OBJECTIVES: To analyse the cost and describe the degree of control of the hypercholesterolaemia of type-2 diabetic (DM2) patients according to different groups and scientific societies. DESIGN: Retrospective cross-sectional study. SETTING: Rural health area. PATIENTS: All DM2 patients monitored in the health area (n = 338). MEASUREMENTS AND MAIN RESULTS: Gathering of data on clinical histories, determination of cardiovascular risk, LDL-C concentration and total/HDL cholesterol index. DM2 prevalence was 3.08%; annual incidence, 2.55/1000; 45.2% presented hypercholesterolaemia; 16.9% received lipid-lowering treatment; and 20.1% (n = 68) had DM2 with cardiovascular disease. According to the criteria of the GEDAPS-99, European Consensus-98 (Framingham table), Sheffield Group (objectives of the European Consensus-98) and PAPPS-99 for primary prevention, 59.3%, 58.4%, 24.5% and 17.7%, respectively, of hypercholesterolaemic patients were poorly controlled. The percentages of hypercholesterolaemic patients who in each case should receive treatment were: 64.9%, 66.1%, 36.4% and 29.6%. Expenditure in thousands of pesetas every 28 days to achieve proper control of these patients was 282, 423, 274 and 117. The criteria on secondary prevention of the GEDAPS-99 and European Consensus-98 gave figures of 81% and 72.4%, respectively, of poor control of Hypercholesterolaemia. 82.7% and 77.5% of these patients should receive treatment. Expenditure in thousands of pesetas every 28 days to achieve proper control of these patients was 342 and 210. CONCLUSIONS: The degree of control and the costs of hypercholesterolaemia in both primary and secondary prevention vary enormously, depending on the criterion used by the group or scientific society.
OBJECTIVES: To analyse the cost and describe the degree of control of the hypercholesterolaemia of type-2 diabetic (DM2) patients according to different groups and scientific societies. DESIGN: Retrospective cross-sectional study. SETTING: Rural health area. PATIENTS: All DM2 patients monitored in the health area (n = 338). MEASUREMENTS AND MAIN RESULTS: Gathering of data on clinical histories, determination of cardiovascular risk, LDL-C concentration and total/HDL cholesterol index. DM2 prevalence was 3.08%; annual incidence, 2.55/1000; 45.2% presented hypercholesterolaemia; 16.9% received lipid-lowering treatment; and 20.1% (n = 68) had DM2 with cardiovascular disease. According to the criteria of the GEDAPS-99, European Consensus-98 (Framingham table), Sheffield Group (objectives of the European Consensus-98) and PAPPS-99 for primary prevention, 59.3%, 58.4%, 24.5% and 17.7%, respectively, of hypercholesterolaemic patients were poorly controlled. The percentages of hypercholesterolaemic patients who in each case should receive treatment were: 64.9%, 66.1%, 36.4% and 29.6%. Expenditure in thousands of pesetas every 28 days to achieve proper control of these patients was 282, 423, 274 and 117. The criteria on secondary prevention of the GEDAPS-99 and European Consensus-98 gave figures of 81% and 72.4%, respectively, of poor control of Hypercholesterolaemia. 82.7% and 77.5% of these patients should receive treatment. Expenditure in thousands of pesetas every 28 days to achieve proper control of these patients was 342 and 210. CONCLUSIONS: The degree of control and the costs of hypercholesterolaemia in both primary and secondary prevention vary enormously, depending on the criterion used by the group or scientific society.
Authors: W M Verschuren; D R Jacobs; B P Bloemberg; D Kromhout; A Menotti; C Aravanis; H Blackburn; R Buzina; A S Dontas; F Fidanza Journal: JAMA Date: 1995-07-12 Impact factor: 56.272